Home > Insider Trading > Filing (0001209191-18-052843)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1382101	Sutro Biopharma Inc	STRO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1294939	H Daniel Petree	C/O Sutro Biopharma, Inc. 310 Utah Avenue, Suite 150 South San Francisco CA 94080		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-10-01	314	$5.81	314	No	4	M	Indirect	Daniel H. Petree and Susan M. Toeniskoetter Trust dated July 25, 1997
Common Stock	Disposition	2018-10-01	122	$15.00	192	No	4	S	Indirect	Daniel H. Petree and Susan M. Toeniskoetter Trust dated July 25, 1997

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	Daniel H. Petree and Susan M. Toeniskoetter Trust dated July 25, 1997
No	4	S	Indirect	Daniel H. Petree and Susan M. Toeniskoetter Trust dated July 25, 1997

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock Warrant (right to buy)	Disposition	2018-10-01	314	$0.00	314	$5.81

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Footnotes

These securities are held of record by the reporting person and his spouse as trustees of the Daniel H. Petree and Susan M. Toeniskoetter Trust dated July 25, 1997.
On October 1, 2018, the reporting person exercised a warrant to purchase 314 shares of issuer's common stock for $5.81 per share. The reporting person paid the exercise price on a cashless basis, resulting in the issuer withholding 122 of the shares to pay the exercise price and issuing to the reporting person the remaining 192 shares.
The warrant has a net exercise provision under which the holder, in lieu of paying the exercise price in cash, can surrender the warrant and receive a net number of shares of common stock based on the fair market value of such stock at the time of exercise, after deducting the aggregate exercise price.
The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised.